GTSM:6472

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Bora Pharmaceuticals Co., LTD. engages in the research, development, production, marketing, sale, and distribution of pharmaceutical products worldwide. More Details


Snowflake Analysis

High growth potential with adequate balance sheet.

Share Price & News

How has Bora Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6472 is more volatile than 75% of TW stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 6472's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of TW stocks.


Market Performance


7 Day Return

8.9%

6472

-0.9%

TW Pharmaceuticals

2.0%

TW Market


1 Year Return

45.3%

6472

31.8%

TW Pharmaceuticals

31.2%

TW Market

Return vs Industry: 6472 exceeded the TW Pharmaceuticals industry which returned 31.8% over the past year.

Return vs Market: 6472 exceeded the TW Market which returned 31.2% over the past year.


Shareholder returns

6472IndustryMarket
7 Day8.9%-0.9%2.0%
30 Day-14.9%-8.0%10.6%
90 Day-6.0%-15.2%22.8%
1 Year46.9%45.3%34.1%31.8%35.8%31.2%
3 Year666.9%643.8%39.5%31.9%58.3%40.5%
5 Year354.8%326.4%10.5%2.0%133.0%92.1%

Long-Term Price Volatility Vs. Market

How volatile is Bora Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bora Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

47.39x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 6472 (NT$164) is trading above our estimate of fair value (NT$74.35)

Significantly Below Fair Value: 6472 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 6472 is poor value based on its PE Ratio (45.5x) compared to the TW Pharmaceuticals industry average (17.9x).

PE vs Market: 6472 is poor value based on its PE Ratio (45.5x) compared to the TW market (18.6x).


Price to Earnings Growth Ratio

PEG Ratio: 6472 is good value based on its PEG Ratio (0.5x)


Price to Book Ratio

PB vs Industry: 6472 is overvalued based on its PB Ratio (4.4x) compared to the TW Pharmaceuticals industry average (2.1x).


Next Steps

Future Growth

How is Bora Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

88.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6472's forecast earnings growth (88.6% per year) is above the savings rate (0.8%).

Earnings vs Market: 6472's earnings (88.6% per year) are forecast to grow faster than the TW market (18.7% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 6472's revenue (69.1% per year) is forecast to grow faster than the TW market (11.2% per year).

High Growth Revenue: 6472's revenue (69.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 6472's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Bora Pharmaceuticals performed over the past 5 years?

42.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6472 has a high level of non-cash earnings.

Growing Profit Margin: 6472's current net profit margins (12.6%) are lower than last year (23.4%).


Past Earnings Growth Analysis

Earnings Trend: 6472's earnings have grown significantly by 42.7% per year over the past 5 years.

Accelerating Growth: 6472's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 6472 had negative earnings growth (-46.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (23.3%).


Return on Equity

High ROE: 6472's Return on Equity (9.5%) is considered low.


Next Steps

Financial Health

How is Bora Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: 6472's short term assets (NT$1.5B) exceed its short term liabilities (NT$662.1M).

Long Term Liabilities: 6472's short term assets (NT$1.5B) exceed its long term liabilities (NT$1.1B).


Debt to Equity History and Analysis

Debt Level: 6472's debt to equity ratio (57.6%) is considered high.

Reducing Debt: 6472's debt to equity ratio has reduced from 67.3% to 57.6% over the past 5 years.

Debt Coverage: 6472's debt is not well covered by operating cash flow (16.3%).

Interest Coverage: 6472's interest payments on its debt are well covered by EBIT (14.3x coverage).


Balance Sheet


Next Steps

Dividend

What is Bora Pharmaceuticals's current dividend yield, its reliability and sustainability?

0.90%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 6472's dividend (0.94%) isn’t notable compared to the bottom 25% of dividend payers in the TW market (2.09%).

High Dividend: 6472's dividend (0.94%) is low compared to the top 25% of dividend payers in the TW market (5.15%).


Stability and Growth of Payments

Stable Dividend: 6472 is not paying a notable dividend for the TW market, therefore no need to check if payments are stable.

Growing Dividend: 6472 is not paying a notable dividend for the TW market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: 6472 is not paying a notable dividend for the TW market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 6472's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.7yrs

Average board tenure


CEO

Bobby Sheng

no data

Tenure

Mr. Pao-Shi Sheng, also known as Bobby, is the Principle Founder, the Chairman and Chief Executive Officer of Bora Corporation and Bora Pharmaceuticals Inc. (alternate name, Bora Pharmaceuticals Co., Ltd.)...


Board Members

NamePositionTenureCompensationOwnership
Pao-Shi Sheng
Chairman & CEOno datano datano data
Xin Li
Supervisor no datano datano data
Xin Yi Lai
Supervisor no datano datano data
Guan Bai Chen
Representative Directorno datano datano data
Yi-Qin Li
Independent Director0.67yrno datano data
Rui-Yi Lin
Independent Director0.67yrno datano data
Ming-Rong Lai
Independent Director0.67yrno datano data
Shih-Min Chen
Director0.67yrno datano data

0.7yrs

Average Tenure

Experienced Board: 6472's board of directors are not considered experienced ( 0.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.8%.


Top Shareholders

Company Information

Bora Pharmaceuticals Co., LTD.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bora Pharmaceuticals Co., LTD.
  • Ticker: 6472
  • Exchange: GTSM
  • Founded: 2007
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NT$9.254b
  • Shares outstanding: 54.12m
  • Website: https://www.bora-corp.com

Number of Employees


Location

  • Bora Pharmaceuticals Co., LTD.
  • No. 69, Xing’ai Road
  • 6th Floor
  • Taipei
  • 114
  • Taiwan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
6472GTSM (Taipei Exchange)YesCommon StockTWTWDOct 2014

Biography

Bora Pharmaceuticals Co., LTD. engages in the research, development, production, marketing, sale, and distribution of pharmaceutical products worldwide. It manufactures and sells generic, brand, and over-t...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/26 17:08
End of Day Share Price2021/01/26 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.